Property:Inclusion criteria
This is a property of type Text.
L
Lyckholm et al. (2012): A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders +
≥18 years old, currently receiving, or had received, chemotherapy as part of their cancer treatment were asked if they have had any loss or change in their sense of taste or smell since starting chemotherapy: those answering “yes” were invited to participate in the study +
M
Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients +
Suffering cancer without primary involvement or renal metastasis; being candidate for administration of 70-100 mg/m2 cisplatin; 20-80 years old, creatinine (Cr)<1.5 mg/dL; normal hearing; no underlying nephropathy; performance status of 0-2 of Karnofsky +
Mansouri et al. (2016): The Effect of Aloe Vera Solution on Chemotherapy-Induced Stomatitis in Clients with Lymphoma and Leukemia: A Randomized Controlled Clinical Trial +
Age > 18 years; acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL); being under chemotherapy +
Mansourian et al. (2015): The effect of "curcuma Longa" topical gel on radiation -induced oral mucositis in patients with head and neck cancer +
Minimum age of 18 years, presence of head and neck cancer, minimum radiation dose of 50 Gy (the least dose resulting in mucositis), the ability of patient to use topical gel (by his/her or examiner’s report), minimally 50% of patient’s oral cavity in radiation field (according to the radiotherapist’s opinion) +
Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia +
Histologically confirmed advanced stage tumor at any site, loss of >5% of ideal or preillness body weight in the previous 3 months with or without abnormal values of proinflammatory cytokines predictive of the onset of clinical cachexia, and a life expectancy ≥ 4 months, were eligible. Patients could be receiving concomitant antineoplastic chemotherapy or hormone therapy with palliative intent or supportive care. +
Margalit et al. (2012): Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study +
Men, 40 to 84 years old at baseline (1982), who received radiation therapy +
Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial +
Proven indication for adjuvant external beam radiotherapy of the pelvis after macroscopically complete resection of a pelvic malignancy; age >18 years; given informed consent before starting the treatment +
Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer +
Age > 18 years; squamous cell carcinoma of the mouth, pharynx or larynx; performance status 0-1; ability to eat an adequate oral diet; no previous radiotherapy in the head and neck region; adequate bone marrow, liver and renal functions; no history of allergies to testing compounds +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
Patients who were chemotherapy-naïve, were due to receive a moderately- or highly-emetogenic chemotherapy regimen, were at least 18 years old, had a baseline Karnofsky score >60, had no known concurrent neoplasms or illnesses that induced nausea independent of chemotherapy, and did not self-prescribe therapies or complementary products used for nausea. +
Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer +
- Recently diagnosed stage I or stage II squamous cell carcinoma of one of the following sites: tongue, gum or mouth, oropharynx, hypopharynx, pharynx, or laryn (carcinoma in situ also eligible)
- Between 20 and 79 years of age
- Completed treatment for the first cancer (generally radiation therapy or surgical excision), considered free of cancer at any site at entry into the trial
- No significant comorbidities
- No use of supplements of retinol, b-carotene, vitamin E, or selenium within the past year (multivitamin use allowed) +
Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial +
Patients diagnosed with a single, low‑grade, superficial bladder tumor, less than 3 cm in
diameter, who had undergone TUR +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
- Patients with the diagnosis of chronic phase CML for less than 1 year
- No prior treatment except with hydroxyurea and/or leukopheresis for less than 7 days (splenectomy allowed)
- Patients with myelofibrosis and agnogenic myeloid metaplasia only with positive Ph chromosome test +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
- Suitability for platinum-based chemotherapy
- Histologically or cytologically confirmed NSCLC, SCLC or mesothelioma
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2
- Adequate organ function defined as an absolute neutrophil count >1.5×109/L, white cell count >3×109/L, platelet count >100×109/L, serum creatinine ≤1.25 upper level of normal, creatinine clearance >50 mL/min (EDTA) or >60 mL/min (Cockroft and Gault formula) for cisplatin or >40 mL/min for carboplatin
- Estimated life expectancy of at least 12 weeks +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Patients with stage III or IV Head and Neck Squamous Cell Carcinoma scheduled for 7 weeks of concurrent cisplatin and radiation, biopsy-proven locally advanced Head and Neck Squamous Cell Carcinoma, in oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or paranasal sinuses, Eastern Cooperative Oncology Group performance status of 0-2 +
Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy +
Histology proven evidence of carcinomas of lung, breast and ovary and would be treated with 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapeutic drugs, patients receiving paclitaxel either as first line or second line chemotherapeutic drug, either as a single agent or in combinations and with baseline clinical evaluation negative for any existing peripheral neuropathy; when paclitaxel is administered as second like drug, the exact details of previous chemotherapeutic agents would be necessary; those who have already received platinum, vincristine would be included provided no peripheral neuropathy is detected at the time of enrollment +
Montazeri et al. (2013): Effect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients +
Age over 18, having the experience of chemotherapy with nausea and vomiting, having at least two chemotherapy episodes. Consists of 50-100 mg Cisplatin, with or without other chemotherapy agents with similar amount and prescription in two chemotherapy cycles without having any plans for radiotherapy among cycles, presence in ward for 24 hours ( in order to investigate the PRN), having no nausea and vomiting experiences for some reasons except for chemotherapy, lack of receiving PRN in 24 past hours, lack of treatment with corticosteroid drugs during considered cycles, lack of afflictions to hepatitis, digestion system block-age, brain malignancy and cerebral metastasis and clotting disorder on the basis of recorded information in files, lack of using the anti-clot drug +
Montazeri et al. (2013): Iranian Red Crescent Medical JournalEffect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. +
? +
Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial +
Karnofsky’s performance status ≥70, receiving curative radiotherapy or chemoradiotherapy, planned treatment was at least 6000cGy total radiation dose of external beam radiotherapy to at least one third of the oral cavity +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
Patients with histopathologically confirmed carcinomas of the cervix or corpus uteri with a significant whole-blood selenium deficiency (i.e., concentration <85 µg/L) after curative surgical treatment +